These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 6953613)

  • 1. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K; Djaja S; Richter E
    Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
    [No Abstract]   [Full Text] [Related]  

  • 2. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bezafibrate and delayed action etofibrate in hyperlipidemia].
    Lang PD; Vollmar J
    Dtsch Med Wochenschr; 1983 Feb; 108(8):302-5. PubMed ID: 6825604
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
    Bruneder H; Klein HJ
    Dtsch Med Wochenschr; 1981 Dec; 106(49):1653-6. PubMed ID: 7308007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
    Schatton W; Holm E
    Fortschr Med; 1986 Apr; 104(13):280-2. PubMed ID: 3699655
    [No Abstract]   [Full Text] [Related]  

  • 6. Favourable effect of combined Miscleron-Xavin treatment on HDL-cholesterol level.
    Pados G; Kusztos D; Németh-Csóka M; Valyon M; Farkas K
    Ther Hung; 1983; 31(2):59-61. PubMed ID: 6571183
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
    Wechsler JG; Hutt V; Klör HU; Ditschuneit H
    Artery; 1980; 8(6):519-29. PubMed ID: 7259531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
    Słowińska R; Bochenek W; Unlot J
    Pol Tyg Lek; 1983 Apr; 38(17):529-32. PubMed ID: 6356087
    [No Abstract]   [Full Text] [Related]  

  • 10. [Lowering lipids rapidly and permanently with etofibrate].
    von Bock und Polach U
    Med Klin; 1982 Jan; 77(3):35-8. PubMed ID: 7057729
    [No Abstract]   [Full Text] [Related]  

  • 11. [Bezafibrate in primary hyperlipidemias (author's transl)].
    Wechsler JG; Hutt V; Klör HU; Bode G; Ditschuneit H
    Klin Wochenschr; 1982 Jan; 60(2):97-105. PubMed ID: 7070008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacology and mechanism of action of etofibrate].
    Schatton W
    Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
    Prager R; Schernthaner G; Kostner GM; Mühlhauser I; Zechner R; Dorda W
    Atherosclerosis; 1982 Jun; 43(2-3):321-7. PubMed ID: 6810904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
    Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract]   [Full Text] [Related]  

  • 15. [Atherosclerosis treatment with etofibrate retard. New perspectives].
    Degenring FH; Schatton W; Hotz W
    Fortschr Med; 1983 Aug; 101(30):1391-6. PubMed ID: 6618402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of diet and drug therapy on the level of high density lipoprotein cholesterol in patients with primary hyperlipoproteinemia].
    Padosh D; Kustosh D; Puchok I; Dem'ianova N; Audikovski M
    Klin Med (Mosk); 1981 Sep; 59(9):45-8. PubMed ID: 7311430
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic effect of etofyllinclofibrate in disordered lipid and uric acid metabolism].
    Fiegel G
    Med Welt; 1982 Mar; 33(9):334-6. PubMed ID: 7045566
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.
    Mordasini R; Riesen W; Oster P; Keller M; Middelhoff G; Lang PD
    Atherosclerosis; 1981 Oct; 40(2):153-8. PubMed ID: 6796096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.